nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
African American race but not genome-wide ancestry is negatively associated with atrial fibrillation among postmenopausal women in the Women's Health Initiative
|
Perez, Marco V. |
|
2013 |
166 |
3 |
p. 566-572.e1 5155 p. |
artikel |
2 |
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis
|
Habara, Seiji |
|
2013 |
166 |
3 |
p. 527-533.e2 52774 p. |
artikel |
3 |
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
|
Garcia, David A. |
|
2013 |
166 |
3 |
p. 549-558 10 p. |
artikel |
4 |
Appropriate test selection for single-photon emission computed tomography imaging: Association with clinical risk, posttest management, and outcomes
|
Aldweib, Nael |
|
2013 |
166 |
3 |
p. 581-588 8 p. |
artikel |
5 |
A prospective regional registry of ST-elevation myocardial infarction in Central Romania: Impact of the Stent for Life Initiative recommendations on patient outcomes
|
Benedek, Imre |
|
2013 |
166 |
3 |
p. 457-465 9 p. |
artikel |
6 |
Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy
|
Kobayashi, Taisei |
|
2013 |
166 |
3 |
p. 503-511 9 p. |
artikel |
7 |
Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy
|
Ndrepepa, Gjin |
|
2013 |
166 |
3 |
p. 534-540 7 p. |
artikel |
8 |
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
|
Turakhia, Mintu P. |
|
2013 |
166 |
3 |
p. 573-580 8 p. |
artikel |
9 |
Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial
|
Shah, Binita |
|
2013 |
166 |
3 |
p. 519-526.e2 52082 p. |
artikel |
10 |
Correction
|
|
|
2013 |
166 |
3 |
p. 604- 1 p. |
artikel |
11 |
Correction
|
|
|
2013 |
166 |
3 |
p. 604- 1 p. |
artikel |
12 |
Differences in the outcome of patients undergoing percutaneous coronary interventions at teaching versus non-teaching hospitals
|
Sandhu, Amneet |
|
2013 |
166 |
3 |
p. 401-408 8 p. |
artikel |
13 |
Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial
|
Alexander, John H. |
|
2013 |
166 |
3 |
p. 559-565.e1 5092 p. |
artikel |
14 |
Editorial Board
|
|
|
2013 |
166 |
3 |
p. A6- 1 p. |
artikel |
15 |
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
|
Brilakis, Emmanouil S. |
|
2013 |
166 |
3 |
p. 474-480 7 p. |
artikel |
16 |
Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women)
|
Hess, Connie N. |
|
2013 |
166 |
3 |
p. 421-428.e1 3860 p. |
artikel |
17 |
Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
|
Lincoff, A. Michael |
|
2013 |
166 |
3 |
p. 429-434.e1 3912 p. |
artikel |
18 |
Exercise-induced pulmonary hypertension in systemic sclerosis: A multifactorial entity
|
Baptista, Rui |
|
2013 |
166 |
3 |
p. e13- 1 p. |
artikel |
19 |
Exercise-mediated changes in high-density lipoprotein: Impact on form and function
|
Blazek, Alisa |
|
2013 |
166 |
3 |
p. 392-400 9 p. |
artikel |
20 |
High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men
|
Eggers, Kai M. |
|
2013 |
166 |
3 |
p. 541-548.e1 4940 p. |
artikel |
21 |
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patient outcomes, rate of appropriate and inappropriate interventions, and complications
|
Vriesendorp, Pieter A. |
|
2013 |
166 |
3 |
p. 496-502 7 p. |
artikel |
22 |
Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial
|
Kirchhof, Paulus |
|
2013 |
166 |
3 |
p. 442-448 7 p. |
artikel |
23 |
Information for Readers
|
|
|
2013 |
166 |
3 |
p. A7- 1 p. |
artikel |
24 |
Letter to the Editor regarding “Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium”
|
Blankfield, Robert P. |
|
2013 |
166 |
3 |
p. e9- 1 p. |
artikel |
25 |
Morbidity in children and adolescents after surgical correction of truncus arteriosus communis
|
O'Byrne, Michael L. |
|
2013 |
166 |
3 |
p. 512-518 7 p. |
artikel |
26 |
Overview of the 2012 Food and Drug Administration circulatory system devices panel meeting on the reclassification of external counterpulsation, intra-aortic balloon pump, and non–roller-type cardiopulmonary bypass blood pump devices
|
Minha, Sa'ar |
|
2013 |
166 |
3 |
p. 414-420 7 p. |
artikel |
27 |
Predictors of discordance between physicians' and patients' appraisals of health-related quality of life in atrial fibrillation patients: Findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation Trial
|
von Eisenhart Rothe, Alexander |
|
2013 |
166 |
3 |
p. 589-596.e1 5372 p. |
artikel |
28 |
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: Assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial
|
Mancini, G.B. John |
|
2013 |
166 |
3 |
p. 481-487 7 p. |
artikel |
29 |
Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION)
|
Mentz, Robert J. |
|
2013 |
166 |
3 |
p. 488-495.e1 4463 p. |
artikel |
30 |
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial
|
Kimmel, Stephen E. |
|
2013 |
166 |
3 |
p. 435-441.e2 43666 p. |
artikel |
31 |
Regional systems of care for ST-elevation myocardial infarction: Do they save lives?
|
Henry, Timothy D. |
|
2013 |
166 |
3 |
p. 389-391 3 p. |
artikel |
32 |
Renal dysfunction may predict new onset heart failure
|
Balta, Sevket |
|
2013 |
166 |
3 |
p. e5- 1 p. |
artikel |
33 |
Response to letter by Balta et al regarding “Renal dysfunction and long-term risk of heart failure after coronary artery bypass grafting”
|
Holzmann, Martin J. |
|
2013 |
166 |
3 |
p. e7- 1 p. |
artikel |
34 |
Response to letter by Messeri et al
|
Palmerini, Tullio |
|
2013 |
166 |
3 |
p. e19- 1 p. |
artikel |
35 |
Response to Letter to the Editor by Blankfield regarding “Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium.”
|
White, William B. |
|
2013 |
166 |
3 |
p. e11- 1 p. |
artikel |
36 |
Response to Letter to the Editor by Rui Baptista, M.D., Rogério Teixeira, M.D.
|
Gargani, Luna |
|
2013 |
166 |
3 |
p. e15-e16 nvt p. |
artikel |
37 |
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non–ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome trial
|
Bagai, Akshay |
|
2013 |
166 |
3 |
p. 466-473.e1 4265 p. |
artikel |
38 |
Table of Contents
|
|
|
2013 |
166 |
3 |
p. A1-A5 nvt p. |
artikel |
39 |
The Coronary Artery Disease and Renal Failure (CAD-REF) registry: Trial design, methods, and aims
|
Brand, Eva |
|
2013 |
166 |
3 |
p. 449-456.e1 4112 p. |
artikel |
40 |
The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: From falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time?
|
Cai, Qiangjun |
|
2013 |
166 |
3 |
p. 409-413 5 p. |
artikel |
41 |
The need to know crude event rates in meta-analysis
|
Messori, Andrea |
|
2013 |
166 |
3 |
p. e17- 1 p. |
artikel |
42 |
Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience
|
Mampuya, Warner M. |
|
2013 |
166 |
3 |
p. 597-603 7 p. |
artikel |